Impact of growth hormone (GH) treatment on circulating Nt-proBNP concentrations and on cardiac function in adult GH-deficient patients

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 72, Issue 5, 2012, Pages 387-394

  Gruson, Damien ^a,b   Alexopoulou, Orsalia ^a,b   Pasquet, Agnès ^b   Cumps, Jean ^a   Ketelslegers, Jean Marie ^a   Maiter, Dominique ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Biomarkers; Cardiac function; Growth hormone therapy; Hypopituitarism; Nt proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GROWTH HORMONE; HYDROCORTISONE; THYROXINE;

ADULT; ADULT GROWTH HORMONE DEFICIENCY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; GROWTH HORMONE DEFICIENCY; HEART FUNCTION; HORMONE SUBSTITUTION; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ANALYSIS OF VARIANCE; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CASE-CONTROL STUDIES; CREATININE; EXERCISE TEST; FEMALE; HEART FUNCTION TESTS; HEART RATE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 84865323486     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2012.685887     Document Type: Article

References (47)

1. Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol (Oxf) 2001;54: 137-54. (Pubitemid 32194446)
2. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285-8. (Pubitemid 20229130)
3. Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997;46:75-81. (Pubitemid 27072849)
4. Colao A, Di Somma C, Cuocolo A, Spinelli L, Tedesco N, Pivonello R, Bonaduce D, Salvatore M, Lombardi G. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH defi ciency. J Clin Endocrinol Metab 2001;86:1874-81. (Pubitemid 32472888)
5. ter Maaten JC, de Boer H, Kamp O, Stuurman L, van der Veen EA. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH defi ciency. J Clin Endocrinol Metab 1999;84:2373-80.
6. Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone defi ciency: a meta-analysis. Circulation 2003;108:2648-52. (Pubitemid 37466806)
7. Le Corvoisier P, Hittinger L, Chanson P, Montagne O, Macquin-Mavier I, Maison P. Cardiac effects of growth hormone treatment in chronic heart failure: a meta-analysis. J Clin Endocrinol Metab 2007;92:180-5. (Pubitemid 46067528)
8. Cittadini A, Saldamarco L, Marra AM, Arcopinto M, Carlomagno G, Imbriaco M, Del FD, Vigorito C, Merola B, Oliviero U, Fazio S, Sacca L. Growth hormone defi ciency in patients with chronic heart failure and benefi cial effects of its correction. J Clin Endocrinol Metab 2009;94:3329-36.
9. Cenci MC, Soares DV, Spina LD, de Lima Oliveira Brasil RR, Lobo PM, Mansur VA, Gold J, Michmacher E, Vaisman M, Conceicao FL. Effects of 5 years of growth hormone (GH) replacement therapy on cardiac parameters and physical performance in adults with GH defi ciency. Pituitary 2009;12:322-9.
10. Palmeiro CR, Anand R, Dardi IK, Balasubramaniyam N, Schwarcz MD, Weiss IA. Growth hormone and the cardiovascular system. Cardiol Rev. Forthcoming 2012.
11. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8. (Pubitemid 28366422)
12. Pfi ster R, Schneider CA. Natriuretic peptides BNP and NTpro- BNP: established laboratory markers in clinical practice or just perspectives? Clin Chim Acta 2004;349:25-38. (Pubitemid 39311985)
13. Troughton RW, Richards AM. B-type natriuretic peptides and echocardiographic measures of cardiac structure and function. JACC Cardiovasc Imaging 2009;2:216-25.
14. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-7. (Pubitemid 34556391)
15. Omland T, Persson A, Ng L, O' B rien R, Karlsson T, Herlitz J, Hartford M, Caidahl K. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002;106:2913-8. (Pubitemid 35424741)
16. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-75. (Pubitemid 40239214)
17. Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, Landaas S, Rouleau JL, Domanski MJ, Hall C, Pfeffer MA, Braunwald E. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol 2007;50:205-14. (Pubitemid 47031568)
18. Di AE, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009;120:2177-87.
19. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-63. (Pubitemid 38364624)
20. Rutten JH, Mattace-Raso FU, Steyerberg EW, Lindemans J, Hofman A, Wieberdink RG, Breteler MM, Witteman JC, van den Meiracker AH. Amino-terminal pro-B-type natriuretic peptide improves cardiovascular and cerebrovascular risk prediction in the population: the Rotterdam study. Hypertension 2010;55:785-91.
21. Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, Kronmal RA. N-terminal pro- B-type natriuretic peptide is a major predictor of the development of atrial fi brillation: the Cardiovascular Health Study. Circulation 2009;120:1768-74.
22. Ekman B, Ohman PK, Arnqvist HJ, Lindstrom T, Nystrom FH. Individualized growth hormone substitution with normalized IGF-I levels does not stimulate the renin-angiotensinaldosterone system. Clin Endocrinol (Oxf) 2002;57:473-9. (Pubitemid 35216298)
23. Andreassen M, Faber J, Vestergaard H, Kistorp C, Kristensen LO. N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances. Clin Endocrinol (Oxf) 2007;66:619-25. (Pubitemid 46699526)
24. Johannsson G, Sverrisdottir YB, Ellegard L, Lundberg PA, Herlitz H. GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron and preventing pressure natriuresis. J Clin Endocrinol Metab 2002;87: 1743-9. (Pubitemid 34618504)
25. Wallaschofski H, Saller B, Spilcke-Liss E, Lerch MM, Lohmann T, Eigenthaler M. Effects of growth hormone treatment on B-type natriuretic peptide as a marker of heart failure in adults with growth hormone defi ciency. Horm Metab Res 2006;38:656-61. (Pubitemid 44759216)
26. Lazurova I, Pura M, Wagnerova H, Tajtakova M, Sedlakova M, Tomas L, Payer J, Hruzikova P, Vanuga P, Podoba J, Trejbalova L, Popovic V, Koltowska-Haggstrom M. Effect of growth hormone replacement therapy on plasma brain natriuretic peptide concentration, cardiac morphology and function in adults with growth hormone defi ciency. Exp Clin Endocrinol Diabetes 2010;118:172-6.
27. Andreassen M, Faber J, Kjaer A, Petersen CL, Kristensen LO. Cardiac function in growth hormone defi cient patients before and after 1 year with replacement therapy: a magnetic resonance imaging study. Pituitary 2011;14:1-10.
28. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantifi cation: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantifi cation Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18: 1440-63. (Pubitemid 41821197)
29. Januzzi JL, Jr., Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95: 948-54. (Pubitemid 40487743)
30. Van Beneden R, Gurne O, Selvais PL, Ahn SA, Robert AR, Ketelslegers JM, Pouleur HG, Rousseau MF. Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. J Card Fail 2004;10:490-5.
31. B rabant G, Wallaschofski H. Normal levels of serum IGF-I: determinants and validity of current reference ranges. Pituitary 2007;10:129-33. (Pubitemid 46863727)
32. Brabant G, von zur MA, Wuster C, Ranke MB, Kratzsch J, Kiess W, Ketelslegers JM, Wilhelmsen L, Hulthen L, Saller 5. B, Mattsson A, Wilde J, Schemer R, Kann P. Serum insulinlike growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 2003;60:53-60. (Pubitemid 36928670)
33. Merola B, Cittadini A, Colao A, Longobardi S, Fazio S, Sabatini D, Sacca L, Lombardi G. Cardiac structural and functional abnormalities in adult patients with growth hormone defi ciency. J Clin Endocrinol Metab 1993;77:1658-61. (Pubitemid 24000930)
34. Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone defi ciency: a meta-analysis. Circulation 2003;108:2648-52. (Pubitemid 37466806)
35. Isgaard J, Tivesten A, Friberg P, Bengtsson BA. The role of the GH/IGF-I axis for cardiac function and structure. Horm Metab Res 1999;31:50-4. (Pubitemid 29169475)
36. Colao A, Di Somma C, Cuocolo A, Spinelli L, Tedesco N, Pivonello R, Bonaduce D, Salvatore M, Lombardi G. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH defi ciency. J Clin Endocrinol Metab 2001;86:1874-81. (Pubitemid 32472888)
37. Climent VE, Pico A, Sogorb F, Aznar S, Lip GY, Marin F. Growth hormone therapy and the heart. Am J Cardiol 2006; 97:1097-102.
38. Jin H, Yang R, Lu H, Ogasawara AK, Li W, Ryan A, Peale F, Paoni NF. Effects of early treatment with growth hormone on infarct size, survival, and cardiac gene expression after acute myocardial infarction. Growth Horm IGF Res 2002; 12:208-15. (Pubitemid 35230192)
39. Mulumba M, Cemeus C, Dumont L, du SP, Ong H, Marleau S. Recombinant bovine growth hormone-induced reduction of atrial natriuretic peptide is associated with improved left ventricular contractility and reverse remodeling in cardiomyopathic UM-X7.1 hamsters with congestive heart failure. Growth Horm IGF Res 2007;17:96-103. (Pubitemid 46552886)
40. Verhelst J, Abs R. Long-term growth hormone replacement therapy in hypopituitary adults. Drugs 2002;62:2399-412. (Pubitemid 35316388)
41. Ho KY, Kelly JJ. Role of growth hormone in fl uid homeostasis. Horm Res 1991;36(Suppl. 1):44-8.
42. Moller J, Nielsen S, Hansen TK. Growth hormone and fl uid retention. Horm Res 1999;51(Suppl. 3):116-20.
43. Alexopoulou O, Beguin C, De NP, Maiter D. Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. Eur J Endocrinol 2004;150:1-8. (Pubitemid 38159735)
44. Hogenhuis J, Voors AA, Jaarsma T, Hillege HL, Boomsma F, van Veldhuisen DJ. Infl uence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP. Eur J Heart Fail 2005;7:81-6. (Pubitemid 40092496)
45. Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail 2003;5:599-606. (Pubitemid 38043963)
46. Emdin M, Passino C, Del Ry S, Prontera C, Galetta F, Clerico A. Infl uence of gender on circulating cardiac natriuretic hormones in patients with heart failure. Clin Chem Lab Med 2003;41:686-92. (Pubitemid 36722825)
47. Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC, Frohlich ED. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004;43:1590-5. (Pubitemid 38561338)